Endoscopic sphincterotomy and cholecystectomy in acute biliary pancreatitis. Surgeon. 2016 Apr;14(2):99-108. doi: 10.1016/j.surge.2015.10.002. Epub 2015 Nov 2. Review.
BACKGROUND: This review discusses current insights with regard to biliary tract management during and after acute biliary pancreatitis. METHODS: A MEDLINE and EMBASE search was done and studies were selected based on methodological quality and publication date. The recommendations of recent guidelines are incorporated in this review.
In absence of consensus in the literature, expert opinion is expressed. RESULTS: There is no role for early endoscopic retrograde cholangiopancreatography (ERCP) in patients with (predicted) mild biliary pancreatitis to improve outcome.
In case of persisting choledocholithiasis, ERCP with stone extraction is scheduled electively when the acute event has subsided. Whether early ERCP with sphincterotomy is beneficial in patients with predicted severe pancreatitis remains subject to debate. Regardless of disease severity, in case of concomitant cholangitis urgent endoscopic sphinctero-tomy (ES) is recommended. As a definitive treatment to reduce the risk of recurrent biliary events in the long term, ES is inferior to cholecystectomy and should be reserved for patients considered unfit for surgery. After severe biliary pancreatitis, cholecystectomy should be postponed until all signs of inflammation have subsided. In patients with mild pancreatitis, cholecystectomy during the primary admission reduces the risk of recurrent biliary complications. CON-CLUSION: Recent research has provided valuable data to guide biliary tract management in the setting of acute biliary pancreatitis with great value and benefit for patients and clinicians. Some important clinical dilemmas remain, but it is anticipated that on-going clinical trials will deliver some important insights and additional guidance soon.
179 BIJLAGE WETENSCHAPPELIJKE PUBLICATIES 2013-2014 OPGENOMEN IN PUBMED
PMID: 26553305
Van der Stelt CA, Vermeulen Windsant-van den Tweel AM, Egberts AC, van den Bemt PM, Leendertse AJ, Hermens WA, van Marum RJ, Derijks HJ. The Association Between Potentially Inappropriate Prescribing and Medication-Related Hospital Admissions in Older Patients: A Nested Case Control Study.
Drug Saf. 2016 Jan;39(1):79-87. doi: 10.1007/s40264-015-0361-1.
INTRODUCTION: Medication-related problems can cause serious adverse drug events (ADEs) that may lead to hospitalization of the patient. There are multiple screening methods to detect and reduce potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs). Whether this will result in less medication-related hospitalizations is unknown. The study objective was to assess the risk of preventable medication-related hospital admissions associated with potentially inappropriate prescribing, using the Beers 2012 and the Screening Tool of Older Person’s Prescriptions and the Screening Tool to Alert doctors to Right Treatment (STOPP & START) 2008 criteria.
DESIGN, SETTING AND PARTICIPANTS: A nested case-control study was conducted with a subset of Dutch participants from the Hospital Admissions Related to Medication (HARM) study. Cases were defined as patients aged ≥65 years with a potentially preventable medication-related hospital admission. For each case, one control was selected, matched for age and sex. The primary determinant was the presence of one or more PIMs according to the Beers 2012 and STOPP 2008 criteria. The secondary determinant was the presence of one or more PIMs and PPOs according to the STOPP & START 2008 criteria. The strength of the association between inappropriate prescribing and medication-related hospital admission was evaluated with multivariate logistic regression and expressed as odds ratios (ORs) with 95 % confidence intervals (CIs). RESULTS: The prevalence of Beers 2012 criteria PIMs in the total cohort was 44.4 %.
The prevalence of STOPP & START 2008 criteria PIMs and PPOs were, respectively, 34.1 and 57.7 %. STOPP 2008 criteria PIMs were associated with preventable medication-related hospital admissions [OR adjusted for number of drugs and comorbidities (ORadj) 2.30, 95 % CI 1.30-4.07], whereas there was no association with Beers 2012 criteria PIMs (ORadj 1.49, 95 % CI 0.90-2.47). STOPP PIMs and START PPOs together were also associated with preventable medication-related hospital admissions (ORadj 3.47, 95 % CI 1.70-7.09). CONCLUSION: Our study shows that patients with potentially inappropriate prescribing detected with the STOPP & START 2008 criteria are at risk of preventable medication-related hospital admissions. The STOPP & START 2008 criteria can be used to identify older people at risk of medication-related problems.
PMID: 26553486
De Wit HM, Vervoort GM, Jansen HJ, de Galan BE, Tack CJ. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes’ (ELEGANT) randomized controlled trial. J Intern Med. 2016 Mar;279(3):283-92. doi: 10.1111/joim.12447. Epub 2015 Nov 9.
BACKGROUND: Pronounced weight gain frequently complicates insulin therapy in patients with type 2 diabetes (T2DM). We have previously reported that addition of liraglutide for 26 weeks can reverse insulin-associated weight gain, decrease insulin dose and improve glycaemic control, as compared with continuation of standard insulin treatment. OBJECTIVES: To investigate whether the beneficial effects of liraglutide are sustained up to 52 weeks and whether similar effects could be obtained when liraglutide is added 6 months later. METHODS: Adult T2DM patients with ≥ 4% weight gain within 16 months of insulin therapy completing the first 26-week trial period of open-label addition of liraglutide 1.8 mg day(-1) (n = 26) versus continuation of standard insulin therapy (n = 24) were all treated with liraglutide for another 26 weeks. Results were analysed according to the intention-to-treat principle. RESULTS:
Overall, 24 (92%) and 18 (75%) patients originally assigned to liraglutide and standard therapy, respectively, completed the study. Addition of liraglutide decreased body weight to a similar extend when given in the first 26 weeks (liraglutide group) or second 26 weeks (original standard therapy group): -4.4 vs. -4.3 kg (difference -0.32 kg, 95% confidence in-terval -2.2 to 1.6 kg; P = 0.74). Similar results were also seen in the two groups with regard to decrease in haemoglo-bin A1c (HbA1c ) (-0.77 vs. -0.66%; P = 0.23) and insulin dose (-28 vs. -26 U day(-1) ; P = 0.32). In both groups, 22%
of patients could discontinue insulin. Continuation of liraglutide until 52 weeks led to sustained effects on body weight, HbA1c and insulin-dose requirements. CONCLUSION: In T2DM patients with pronounced insulin-associated weight gain, addition of liraglutide within 2 years leads to sustained reversal of body weight, improved glycaemic control and decrease in insulin dose. Thus, liraglutide offers a valuable therapeutic option.
PMID: 26560803
Morroy G, Van Der Hoek W, Nanver ZD, Schneeberger PM, Bleeker-Rovers CP, Van Der Velden J, Coutinho RA. The health status of a village population, 7 years after a major Q fever outbreak. Epidemiol Infect. 2015 Nov 12:1-10.
From 2007 to 2010, The Netherlands experienced a major Q fever outbreak with more than 4000 notifications.
Previous studies suggested that Q fever patients could suffer long-term post-infection health impairments, especially fatigue. Our objective was to assess the Coxiella burnetii antibody prevalence and health status including fatigue, and assess their interrelationship in Herpen, a high-incidence village, 7 years after the outbreak began. In 2014, we invited all 2161 adult inhabitants for a questionnaire and a C. burnetii indirect fluorescence antibody assay (IFA). The health status was measured with the Nijmegen Clinical Screening Instrument (NCSI), consisting of eight subdomains including fatigue. Of the 70•1% (1517/2161) participants, 33•8% (513/1517) were IFA positive. Of 147 participants who were IFA positive in 2007, 25 (17%) seroreverted and were now IFA negative. Not positive IFA status, but age <50 years, smoking and co-morbidity, were independent risk factors for fatigue. Notified participants reported significantly more often fatigue (31/49, 63%) than non-notified IFA-positive participants (150/451, 33%). Although fatigue is a common sequel after acute Q fever, in this community-based survey we found no difference in fatigue levels between partici-pants with and without C. burnetii antibodies.
PMID: 26564912
Boersma D, Kornmann VN, van Eekeren RR, Tromp E, Ünlü Ç, Reijnen MM, de Vries JP. Treatment Modalities for Small Saphenous Vein Insufficiency: Systematic Review and Meta-analysis. J Endovasc Ther.
2016;23:199-211.
PURPOSE: To investigate and compare the anatomical success rates and complications of the treatment modalities for small saphenous vein (SSV) incompetence. METHODS: A systematic literature search was performed in PubMed, EMBASE, and the Cochrane Library on the following therapies for incompetence of SSVs: surgery, endovenous laser ablation (EVLA), radiofrequency ablation (RFA), ultrasound-guided foam sclerotherapy (UGFS), steam ablation, and mechanochemical endovenous ablation (MOCA). The search found 49 articles (5 randomized controlled trials, 44 cohort studies) reporting on the different treatment modalities: surgery (n=9), EVLA (n=28), RFA (n=9), UGFS (n=6), and MOCA (n=1). A random-effects model was used to estimate the primary outcome of anatomical success, which was defined as closure of the treated vein on follow-up duplex ultrasound imaging. The estimate is reported with the 95% confidence interval (CI). Secondary outcomes were technical success and major complications [paresthesia and deep vein thrombosis (DVT)], given as the weighted means. RESULTS: The pooled anatomical success rate was 58.0%
(95% CI 40.9% to 75.0%) for surgery in 798 SSVs, 98.5% (95% CI 97.7% to 99.2%) for EVLA in 2950 SSVs, 97.1% (95%
181 BIJLAGE WETENSCHAPPELIJKE PUBLICATIES 2013-2014 OPGENOMEN IN PUBMED
CI 94.3% to 99.9%) for RFA in 386 SSVs, and 63.6% (95% CI 47.1% to 80.1%) for UGFS in 494 SSVs. One study reported results of MOCA, with an anatomical success rate of 94%. Neurologic complications were most frequently reported after surgery (mean 19.6%) and thermal ablation (EVLA: mean 4.8%; RFA: mean 9.7%). Deep venous thrombosis was a rare complication (0% to 1.2%). CONCLUSION: Endovenous thermal ablation (EVLA/RFA) should be preferred to surgery and foam sclerotherapy in the treatment of SSV incompetence. Although data on nonthermal techniques in SSV are still sparse, the potential benefits, especially the reduced risk of nerve injury, might be of considerable clinical importance.
PMID: 26580850
Van Rossem CC et al and the Snapshot Appendicitis Collaborative Study Group (B van de Wall). Antibiotic Duration After Laparoscopic Appendectomy for Acute Complicated Appendicitis. JAMA Surg. 2016 Apr;151(4):323-9. doi: 10.1001/jamasurg.2015.4236
IMPORTANCE: Optimal duration of antibiotic treatment to reduce infectious complications after an appendectomy for acute complicated appendicitis remains unclear. OBJECTIVE: To investigate the effect of antibiotic duration on infecti-ous complications after laparoscopic appendectomy for acute complicated appendicitis. DESIGN, SETTING, AND PAR-TICIPANTS: National multicenter prospective, observational, surgical resident-led cohort study conducted in June and July 2014. This study involved academic teaching hospitals (n = 8), community teaching hospitals (n = 38), and com-munity nonteaching hospitals (n = 16), and all consecutive patients (n = 1975) who underwent surgery for suspected acute appendicitis. EXPOSURES: Patients treated laparoscopically for whom the antibiotic regimens were prolonged postoperatively because of complicated appendicitis. MAIN OUTCOMES AND MEASURES: Receiving either 3 or 5 days of antibiotic treatment as planned and additional variables were explored as risk factors for infectious complications using regression analyses. RESULTS: A total of 1975 patients were included in 62 participating Dutch hospitals; 1901 (96.3%) of these underwent an appendectomy for acute appendicitis and laparoscopy was used in 74.4% of these pa-tients (n = 1415). In 415 laparoscopically treated papa-tients, antibiotic treatment was continued for more than 24 hours because of acute complicated appendicitis (29.3%). The prescribed antibiotic duration varied between 2 and 6 days in all of these patients. In 123 patients (29.6%), the length of treatment was adjusted. A shorter duration of antibiotic treatment (3 days instead of 5) had no significant effect on any infectious complication (odds ratio [OR], 0.93; 95% CI, 0.38-2.32; P = .88) or on intra-abdominal abscess development (OR, 0.89; 95% CI, 0.34-2.35; P = .81). Perforation of the appendix was the only independent risk factor for the development of an infectious complication (OR, 4.90; 95% CI, 1.41-17.06; P = .01) and intra-abdominal abscess (OR, 7.46; 95% CI, 1.65-33.66; P = .009) in multivariable regres-sion analysis. CONCLUSIONS AND RELEVANCE: Lengthening of postoperative antibiotic treatment to 5 days was not associated with a reduction in infectious complications. Further restriction of antibiotic treatment can be considered in nonperforated complicated appendicitis.
PMID: 26603437
Johannesma PC, Houweling AC, Menko FH, van de Beek I, Reinhard R, Gille JJ, van Waesberghe JT, Thunnissen E, Starink TM, Postmus PE, van Moorselaar RJ. Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis? Fam Cancer. 2016 Apr;15(2):297-300.
PMID: 26608220
Beernink TM, Wever PC, Hermans MH, Bartholomeus MG. Capnocytophaga canimorsus meningitis
diagnosed by 16S rRNA PCR. Pract Neurol. 2016 Apr;16(2):136-8.
PMID: 26609180
Kist JW, de Keizer B, van der Vlies M, Brouwers AH, Huysmans DA, van der Zant FM, Hermsen R, Stokkel MP, Hoekstra OS, Vogel WV; THYROPET Study Group; other members of the THYROPET Study group are John M.H. de Klerk. Collaborators: van Tinteren H, Paul de Boer J, Morreau H, Huisman MC, Lentjes EG, Links TP, Smit JW, Lavalaye J, de Jager PL, Hoekstra CJ, Gotthardt M, Schelfhout VJ, de Bruin WI, Sivro F, Adam JA, Phan HT, Sloof GW, Wagenaar NR. Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). J Nucl Med. 2016 May;57(5):701-7. doi: 10.2967/jnumed.115.168138. Epub 2015 Nov 25.
PMID: 26616040
Wielders CC, Teunis PF, Hermans MH, van der Hoek W, Schneeberger PM. Kinetics of antibody response to Coxiella burnetii infection (Q fever): Estimation of the seroresponse onset from antibody levels. Epidemics.
2015 Dec;13:37-43.
PMID: 26661393
Van der Bij AK, Frentz D, Bonten MJ; ISIS-AR Study Group (Renders NH). Gram-positive cocci in Dutch ICUs with and without selective decontamination of the oropharyngeal and digestive tract: a retrospective database analysis. J Antimicrob Chemother. 2016 Mar;71(3):816-20. doi: 10.1093/jac/dkv396. Epub 2015 Dec 11.
PMID: 26662794
Van Eijk JJ, Groothuis JT, Van Alfen N. Neuralgic amyotrophy: An update on diagnosis, pathophysiology, and treatment. Muscle Nerve. 2016 Mar;53(3):337-50. doi: 10.1002/mus.25008. Epub 2016 Jan 20. Review.
PMID: 26663464
Brinkman DJ, Keijsers CJ, Tichelaar J, Richir MC, van Agtmael MA. Evaluating pharmacotherapy education:
urgent need for hard outcomes. Br J Clin Pharmacol. 2016 May;81(5):1000-1. doi: 10.1111/bcp.12862.
Epub 2016 Feb 17. No abstract available.
PMID: 26681732
D’Agnolo HM, Drenth JP. Risk factors for progressive polycystic liver disease: where do we stand? Nephrol Dial Transplant. 2016 Jun;31(6):857-9. doi: 10.1093/ndt/gfv417. Epub 2015 Dec 17.
PMID: 26707528
Van Dongen MJ, Falger-Veeken SN. The Risk of a Bicycle Helmet: Hyoid Bone Fracture. Ann Emerg Med.
2016 Jan;67(1):145-6. doi: 10.1016/j.annemergmed.2015.09.012.
PMID: 26711839
Dalton HR, Kamar N, van Eijk JJ, Mclean BN, Cintas P, Bendall RP, Jacobs BC. Hepatitis E virus and neurological injury. Nat Rev Neurol. 2016 Feb;12(2):77-85. doi: 10.1038/nrneurol.2015.234. Epub 2015 Dec 29. Review.
PMID: 26716438
Vogelaar F, Van Erning F, Reimers M, Van Der Linden J, Pruijt J, Van Den Brule A, Bosscha K. The prognostic value of Microsatellite instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients. Mol Med. 2015 Dec 17:1-26. Doi. 10.2119/molmed.2015.00220
183 BIJLAGE WETENSCHAPPELIJKE PUBLICATIES 2013-2014 OPGENOMEN IN PUBMED